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Abstract  
Objective: To identify common genetic variants associated with the presence of brain 
microbleeds (BMB).  
Methods: We performed genome-wide association studies in 11 population-based cohort 
studies and 3 case-control or case-only stroke cohorts. Genotypes were imputed to the 
Haplotype Reference Consortium or 1000 Genomes reference panel. BMB were rated on 
susceptibility-weighted or T2*-weighted gradient echo magnetic resonance imaging 
sequences, and further classified as lobar, or mixed (including strictly deep and infratentorial, 
possibly with lobar BMB). In a subset, we assessed the effects of APOE ε2 and ε4 alleles on 
BMB counts. We also related previously identified cerebral small vessel disease variants to 
BMB. 
Results: BMB were detected in 3,556 of the 25,862 participants, of which 2,179 were strictly 
lobar and 1,293 mixed. One locus in the APOE region reached genome-wide significance for 
its association with BMB (lead SNP rs769449; ORany BMB (95% CI)=1.33 (1.21-1.45); 
p=2.5x10-10).  APOE ε4 alleles were associated with strictly lobar (OR (95% CI)=1.34 (1.19-
1.50); p=1.0x10-6) but not with mixed BMB counts (OR (95% CI)=1.04 (0.86-1.25); p=0.68). 
APOE ε2 alleles did not show associations with BMB counts. Variants previously related to 
deep intracerebral haemorrhage and lacunar stroke, and a risk score of cerebral white matter 
hyperintensity variants, were associated with BMB. 
Conclusions: Genetic variants in the APOE region are associated with the presence of BMB, 
most likely due to the APOE ε4 allele count related to a higher number of strictly lobar BMB. 
Genetic predisposition to small vessel disease confers risk of BMB, indicating genetic overlap 
with other cerebral small vessel disease markers. 
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Introduction 
Brain microbleeds (BMB), also referred to as cerebral microbleeds or cerebral 
microhemorrhages, correspond to hemosiderin deposits as a result of microscopic 
hemorrhages that are visible on magnetic resonance imaging (MRI) sequences.1 The 
frequency of BMB increases with age and with certain pathologies including cerebral small 
vessel disease,2 and in prospective studies BMB can predict risk of ischemic stroke and 
intracerebral hemorrhage (ICH).3, 4 It has been suggested BMB may represent a marker that 
can stratify risk, particularly risk of ICH, in patients taking antithrombotic and anticoagulant 
therapy.5 
Microbleeds can occur in both the cortical area or the cortico-subcortical border (lobar), and 
the subcortical (deep) structures of the brain. BMB in lobar regions are often seen in both 
familial and sporadic cerebral amyloid angiopathy, while deep BMB are more common in 
sporadic deep perforator arteriopathy.6-8 This suggests that different pathophysiological 
mechanisms may underlie BMB in the two locations; a situation similar to that of ICH, where 
the genetic risk factor profiles for lobar and deep hemorrhage have been shown to differ.9  
BMB represent one of a spectrum of MRI markers of cerebral small vessel disease, with 
others including white matter hyperintensities (WMH) and lacunar infarcts.1 Genome-wide 
association studies (GWAS) of these other markers, particularly WMH, have provided novel 
insights into the underlying disease mechanisms.10, 11 However much less is known of the 
genetic basis of BMB.12, 13 We hypothesized that common genetic variants contribute to 
interindividual variation in BMB. Therefore, we performed the largest GWAS on BMB to 
date to evaluate this. In addition to any BMB, we performed separate GWAS for lobar BMB 
and mixed BMB.
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Methods 
Study population 
The study included data from two large initiatives; the Cohorts of Heart and Aging Research 
in Genomic Epidemiology (CHARGE) consortium14 and the UK Biobank 
(http://www.ukbiobank.ac.uk), combined with additional data from the case-control 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu), and the 
MGH-GASROS15 and CROMIS-2 AF4 stroke studies. Together this comprised a total of 
25,862 individuals from 9 population-based and 2 family-based cohort studies, as well as 1 
case-control study and 2 case-only cohorts (Table 1).  
Standard Protocol Approvals, Registrations, and Patient Consents 
The individual studies have been approved by their local Institutional Review boards or ethic 
committees. Written informed consent was obtained from all individuals participating in the 
study.  
Genotyping 
Genotyping was performed on commercially available assays from Illumina or Affymetrix 
and were imputed using the Haplotype Reference Consortium or 1000 Genomes reference 
panels (Supplementary Table 1 http://doi.org/10.5061/dryad.mcvdncjz4). Most cohorts 
included European ancestry individuals only, but a subset of Chinese, Malay and African 
American ancestry (N=130, N=204 and N=422, respectively) was also included. 
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Assessment of brain microbleeds 
MRI scans with field strengths of 1T, 1.5T or 3T and full brain coverage were acquired in 
each participating study (Supplementary Table 2 http://doi.org/10.5061/dryad.mcvdncjz4). 
Definitions of BMB have been described previously.16 Briefly, BMB can be recognized as 
small, hypointense lesions on susceptibility weighted imaging (SWI) sequences or, to a lesser 
extent, on T2*-weighted gradient echo sequences. Although BMB assessment using SWI 
sequences is more sensitive than assessment using T2*-weighted sequences,17, 18 th  clinical 
relevance of this improved sensitivity is debated since it is also less specific.19 Sin e previous 
research has shown differences between risk factors and clinical correlates of BMB in specific 
locations of the brain,6, 8, 20 we further differentiated between strictly lobar, and deep, 
infratentorial or mixed BMB. Cases in which there were microbleeds located in cortical grey 
or subcortical white matter of the brain lobes without any microbleeds in deep or 
infratentorial regions were classified as lobar BMB. Microbleeds in the deep grey matter of 
basal ganglia and thalamus, or in brainstem or cerebellum were classified as deep or 
infratentorial BMB. Due to the low number of cases of BMB, especially the deep and 
infratentorial subtypes, we created one group of mixed BMB cases. Mixed BMB was defined 
as deep or infratentorial BMB, possibly in combination with microbleeds in lobar regions. In 
a minority of cohorts (see Table 1) the data on lobar and/or mixed BMB was not available, 
and therefore the total number of lobar and mixed BMB is slightly less than the total number 
of BMB. Study-specific methodologies for the identification of BMB have been described 
elsewhere.1, 6, 21-30 Since the BMB assessment in the UK Biobank has not been described 
before, additional information regarding the UK Biobank sample, including microbleeds 
assessment, is provided in the Supplementary Information 
(http://doi.org/10.5061/dryad.mcvdncjz4). 
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Genome-wide association studies 
In each participating study, genome-wide association analyses were performed using logistic 
regression under an additive model, adjusted for age, sex, and principal components of 
ancestry to account for population structure (if needed), and family relations (if applicable). 
For each study, variants were filtered by imputation quality (IQ) using an INFO or r2 above 
0.5, minor allele frequency (MAF) above 0.005 and MAF*Ncases*IQ>5. Within the CHARGE 
consortium plus additional case-control and case-only studies, only variants available in at 
least two cohorts were analyzed. Then, genetic variants were filtered using MAF>0.01, after 
which the CHARGE consortium with additional studies and UK Biobank results were meta-
analyzed together. An inverse-variance weighted fixed-effects model was applied in METAL 
using the standard error analysis scheme.31 As a sensitivity analysis, we performed this 
analysis while excluding individuals with dementia and stroke, to investigate whether the 
associations were driven by these diseases. To examine whether there was substantial 
genomic inflation due to population stratification, we inspected the LD score regression 
intercept (Supplementary Table 3 http://doi.org/10.5061/dryad.mcvdncjz4).32 For follow-up 
analyses, only variants present in more than half of the cases were included. HaploReg v4.1 
was used for the functional annotation of the suggestive (p<5x10-6) and genome-wide 
significant (p<5x10-8) variants, and variants in linkage disequilibrium (LD) at a threshold of 
r2>0.8.33 
APOE ε2 and ε4 count analysis 
In the two largest cohorts (i.e. UK Biobank and Rotterdam Study), we investigated the effect 
of APOE ε2 and ε4 allele counts, directly genotyped using a polymerase chain reaction, 
inferred from imputed Haplotype Reference Consortium values of rs429358 and rs7412, or a 
combination of both. Zero-inflated negative binomial regression analysis was performed 
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investigating the association of APOE allele counts with the number of any, lobar and mixed 
BMB, adjusted for age, sex and principal components. For each individual, we counted the 
number of APOE ε2 alleles (ε2ε2 coded as 2, ε2ε3 and ε2ε4 as 1, and ε3ε3, ε3ε4 and ε4ε4 as 
0), and the number of APOE ε4 alleles (ε4ε4 coded as 2, ε2ε4 and ε3ε4 as 1, and ε2ε2, ε2ε3 
and ε3ε34 as 0). We repeated these analyses while setting APOE ε2ε4 values to missing since 
this combines the protective ε2 and the risk-increasing ε4 allele for Alzheimer’s disease and 
may therefore dilute the effects. For these analyses, counts of more than 100 microbleeds 
were considered outliers and removed from the analysis (N=2 in the UK Biobank; N=2 in the 
Rotterdam Study). 
Two-sample Mendelian randomization 
In order to test potential causal effects of cardiovascular risk factors on BMB, we performed a 
two-sample Mendelian randomization using an inverse-variance weighted method 
implemented in the MendelianRandomization R library. Summary statistic data of GWAS 
were acquired for the following traits: type 2 diabetes mellitus,34 systolic and diastolic blood 
pressure, pulse pressure,35 body mass index,36 low density lipoprotein cholesterol, high 
density lipoprotein cholesterol and triglycerides37. 
Related phenotypes 
For independent (r2≤0.8) variants previously associated at genome-wide significance with 
other traits which in turn might be related to BMB, we assessed the association with BMB as 
well. First we examined variants associated with other manifestations of cerebral small vessel 
disease, namely WMH,10, 11, 15 lacunar stroke,38, 39 and ICH39, 40. Second we examined 
associations with traits which have been shown to be predicted by BMB, namely any stroke, 
any ischemic stroke,41, 42 and Alzheimer’s disease43. For each related phenotype, we corrected 
the p-value for significance, dividing 0.05 by the number of single nucleotide polymorphisms 
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(SNPs) tested. Where we had a sufficient number of variants we assessed the cumulative 
association of all variants with BMB using inverse variance weighting across all SNPs, as 
implemented in the gtx package in R. For WMH the effect sizes from the largest GWAS 
sample were used to estimate an overall effect.10 
Data availability statement 
The summary statistics will be made available upon publication on the CHARGE dbGaP site 
under the accession number phs000930.v7.p1.
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Results 
In the combined CHARGE with additional studies and UK Biobank multi-ethnic meta-
analysis, genetic and BMB rating data were available for 25,862 subjects, of whom 3,556 
(13.7%) had BMB. In 2,179 (8.4%) these were lobar and in 1,293 (5.0%) mixed. The 
prevalence of any BMB ranged from 6.5% to 34.3% for studies using T2*-weighted 
sequences for the assessment of BMB, and from 7.0% to 36.8% for studies using SWI 
sequences. After excluding subjects with dementia and stroke 23,032 individuals remained, of 
whom 2,889 (12.5%), 1,843 (8.0%) and 969 (4.2%) had any, lobar, and mixed BMB, 
respectively. A complete overview of the included studies is shown in Table 1. 
Genome-wide association studies 
A quantile-quantile plot showed mild enrichment of genome-wide associations with any BMB 
(Supplementary Figure 1 http://doi.org/10.5061/dryad.mcvdncjz4), and limited genomic 
inflation was observed (λ=1.02, LD score regression intercept=1.02, Supplementary Table 3 
http://doi.org/10.5061/dryad.mcvdncjz4). One locus in the APOE region on chromosome 19 
reached genome-wide significance (lead genetic variant rs769449; OR (95% CI)=1.33 (1.21-
1.45); p=2.5x10-10; Table 2, Figure 1-2, Supplementary Figure 2 
http://doi.org/10.5061/dryad.mcvdncjz4). This effect was stronger for lobar (OR (95% 
CI)=1.32 (1.19-1.47); p=4.3x10-7) than for mixed microbleeds (OR (95% CI)=1.27 (1.11-
1.46); p=5.4x10-4), albeit not significantly. Similar associations were observed for the 
different participating studies (CHARGE with additional studies I2=0, pheterozygosity=0.68; 
CHARGE with additional studies and UK Biobank combined I2=0, pheterozygosity=0.78, 
Supplementary Figure 3 http://doi.org/10.5061/dryad.mcvdncjz4). Functional annotation of 
the genome-wide significant variants and genetic variants in LD (r2>0.8) are presented in 
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Supplementary Table 4 http://doi.org/10.5061/dryad.mcvdncjz4). In the analysis excluding 
individuals with dementia and stroke, the effect estimate for the lead SNP rs769449 did not 
attenuate, although the level of significance slightly decreased reflecting the smaller sample 
size (OR (95% CI)=1.32 (1.20-1.46), p=2.1x10-8, Supplementary Table 5, Supplementary 
Figure 4 http://doi.org/10.5061/dryad.mcvdncjz4). 
APOE ε2 and ε4 count analysis 
To further elucidate whether one of the two APOE genotypes were driving this identified 
genetic association between the APOE region and BMB, we performed a follow-up analysis 
of this finding, assessing the association of APOE ε2 and ε4 allele counts with BMB in the 
two largest cohorts (Rotterdam Study and UK Biobank). The APOE ε4 allele count was 
significantly associated with the number of BMB (OR (95% CI)=1.27 (1.14-1.42); p=1.3 x 
10-5, Table 3). This effect was stronger for lobar than for mixed microbleeds (OR (95% 
CI)=1.33 (1.16-1.52); p=3.5 x 10-5 and OR (95% CI)=1.07 (0.85-1.35); p=0.553, 
respectively). These results did not change after excluding individuals with the APOE ε2ε4 
genotype (Supplementary Table 6 http://doi.org/10.5061/dryad.mcvdncjz4). No significant 
association was found between the APOE ε2 allele count and the number of BMB (OR (95% 
CI)=1.03 (0.86-1.22); p=0.769), also not after removing individuals with the APOE ε2ε4 
genotype (Table 3, Supplementary Table 6 http://doi.org/10.5061/dryad.mcvdncjz4). 
Two-sample Mendelian randomization 
Mendelian randomization analyses testing the influence of cardiovascular risk factors on 
BMB showed positive nominal associations of systolic blood pressure, diastolic blood 
pressure, and triglycerides with any BMB; and of systolic and diastolic blood pressure and 
triglycerides with strictly lobar BMB; as well as triglycerides with deep, infratentorial or 
mixed BMB (Table 4). Only the association of triglycerides with any microbleeds survived 
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multiple testing adjustments (β=0.29, 95% CI=0.09-0.49, p=0.004); the effect estimate of this 
association was stronger for mixed microbleeds (β=0.37, 95% CI=0.09-0.65, p=0.009). 
Related phenotypes 
One genetic variant previously associated with deep ICH and WMH (rs2984613 in the 1q22 
locus) was associated with BMB (OR (95% CI)=1.12 (1.05-1.18), p=1.8 x 10-4), with slightly 
stronger effects on mixed BMB than lobar BMB (OR (95% CI)=1.14 (1.05-1.25), p=3.2 x 10-
3 versus OR (95% CI)=1.09 (1.01-1.17), p=2.2 x 10-2) (Table 5). One variant known to be 
associated with lacunar stroke (rs9515201 in the 13q34 locus) also associated with mixed 
BMB (OR (95% CI)=1.12 (1.02-1.22), p=0.014), but did not associate with lobar BMB (OR 
(95% CI)=0.98 (0.91-1.06), p=0.684). No other cerebral small vessel disease variants were 
individually associated with BMB. Yet cumulatively, genetic variants identified for cerebral 
WMH burden were associated with mixed BMB (OR (95% CI)=1.78 (1.15-2.77); p=0.01), 
but not with lobar BMB (OR (95% CI)=1.02 (0.71-1.45); p=0.93). Also, a cumulative effect 
of previously identified variants for any stroke was found for mixed BMB (OR (95% 
CI)=1.78 (1.09-2.91); p=0.02), which was similar for variants of any ischemic stroke (OR 
(95% CI)=2.00 (1.22-3.27); p=0.006). Full results of the genetic variants previously identified 
for Alzheimer’s disease and stroke are presented in Supplementary Table 7 
(http://doi.org/10.5061/dryad.mcvdncjz4).AC
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Discussion 
We report the first large-scale multi-ethnic genome-wide study of BMB in 25,862 individuals, 
including 3,556 subjects with any BMB of whom 2,179 had strictly lobar and 1,293 mixed 
BMB. We identified an association with BMB in the APOE region, in particular for strictly 
lobar BMB, most likely due to risk associated with APOE ε4 allele counts. 
Our findings are in line with previous studies showing an association between APOE ε4 
genotypes and BMB, in particular with strictly lobar BMB.12 One genetic variant in LD with 
the identified lead SNP (rs769448) is rs429358, which is an APOE missense variant and one 
of the two SNPs constituting APOE ε2/3/4 polymorphisms; this variant was more strongly 
associated with strictly lobar than mixed BMB. In an additional analysis performed in a subset 
of the cohorts we confirmed the known link between APOE ε4 allele count and the number of 
BMB, with stronger effect estimates for the strictly lobar BMB subtype compared to the 
mixed subtype. This association was less pronounced and non-significant for the APOE ε2 
allele count, which is also in accordance with previous studies,12 although this might still be 
due to a lack of power. Other studies did find a significant association between APOE ε2 
alleles and cerebral angiopathy related ICH,9 with stronger estimates for the lobar compared 
to the deep phenotype, which is similar to our study. Stronger effects for ICH in the previous 
study than for BMB in the current study might be due to sampling variability or biological 
differences between the two traits. The APOE locus remained significant with a similar effect 
estimate in the GWAS meta-analysis performed in a dementia- and stroke-free sample, 
indicating that this association was not driven by diseased individuals, and suggesting that 
APOE may already affect BMB risk in a preclinical phase of dementia or stroke.  
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Our findings further suggest that higher triglyceride levels may be causally related to the 
presence of BMB. This relationship between the genetics of triglycerides and BMB, in 
particular for mixed BMB, confirms other studies showing a contribution of cardiovascular 
risk factors to BMB risk, mainly for deep or infratentorial BMB.6 A previous two-sample 
Mendelian randomization study did not find a significant association between the genetics of 
triglycerides and ICH, although the direction of effect for the triglycerides analysis was the 
same as for BMB in the current study.44 However, this positive link between the genetics of 
triglyceride levels and the presence of BMB is in contrast with previous phenotypic 
association studies showing an inverse relationship between triglyceride levels and BMB risk 
in elderly population-based individuals.45, 46 Similarly, lower triglyceride levels have been 
associated with an increased ICH risk.45, 47, 48 Thus, our finding should be interpreted with 
caution and further studies are needed to elucidate the exact causal mechanisms underlying 
lipid profiles over time and BMB risk.  
We also showed that genetic variation previously associated with risk of cerebral small vessel 
disease (i.e. WMH burden, lacunar infarcts and subcortical ICH) are associated with an 
increased risk of BMB, and that this association is restricted to mixed rather than lobar BMB. 
This suggests that mixed BMB have a shared pathophysiological pathway with other features 
of the cerebral small vessel disease spectrum. This is consistent with recent data showing 
genetic sharing between WMH, lacunar infarcts and subcortical ICH.49 Additionally, 
increasing evidence suggests that small vessel arteriopathy may lead to WMH, acute lacunar 
infarction and ICH.50 Our data suggests that mixed BMB are likely to be related to the same 
underlying arterial pathology.  
Associations of the APOE ε4 genotype with decreased cognitive function in the elderly are 
well established.51 Although part of this decline is due to the predisposition to Alzheimer’s 
disease pathology conferred by APOE ε4, our results suggest that another part might be due to 
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vascular mechanisms predisposing to BMB, most likely via cerebral amyloid angiopathy. 
Apart from the APOE locus, no enrichment of previously reported genetic variants for 
Alzheimer’s disease was found. This is in line with a previously published WMH GWAS, in 
which no significant association was found between the identified loci for WMH and 
Alzheimer’s disease.11 It might indicate that APOE is mainly responsible for the genetic 
overlap between BMB and Alzheimer’s disease. Alternatively, the current BMB and 
Alzheimer’s disease GWAS could still be underpowered to identify biological pathways 
playing a role in the development of cerebral small vessel disease subsequently leading to 
Alzheimer’s disease. As another possibility, environmental factors might primarily play a role 
in the link between BMB and neurodegenerative diseases later in life. Although the 19q13 
locus was the only significant BMB locus, we did observe a cumulative effect of stroke SNPs 
on mixed BMB, suggestive of overlapping biological mechanisms underlying the two.  
In this study, we were able to collate most of the GWAS data available worldwide on BMB, 
enabling us to perform by far the largest GWAS meta-analysis of BMB to date. However, our 
study also has limitations. Despite being the largest study to date, the number of individuals 
with BMB was still modest, resulting in a limited power to identify genetic factors related to 
BMB. Significantly larger sample sizes are needed to fully elucidate the genetic contribution 
to BMB. Because of the relatively small number of participants with BMB we combined the 
presence of deep, infratentorial and mixed BMB into one group of “mixed” BMB, even 
though previous research has suggested there may be differences between differences between 
strictly deep and mixed BMB.20 With larger sample sizes it would be interesting to investigate 
whether there are differences in the genetics between deep and infratentorial BMB. The 
percentage of individuals with microbleeds varied across studies, which may be due to a true 
difference in the presence of BMB, due to population differences, e.g. age distributions, 
ethnicities and life style factors. However, the differences in the presence of BMB might also 
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be partially attributable to different sensitivities of the used methodologies, e.g. the magnetic 
field strength of the MRI scanner or the sequence used for rating BMB. In addition, a 
limitation of the current study is the large majority of European ancestry individuals included 
in the analyses, although previous studies have shown differences in the occurrence, 
distribution and associated risks of BMB across different ethnicities.52-54 Therefore, it would 
be valuable for future studies to increase the sample size of non-European ancestry 
individuals in order to be able to perform ancestry-specific analyses. Also, larger reference 
panels would enable us to investigate rare genetic variants as well. Lastly, it may be 
worthwhile to take into account the number of microbleeds instead of treating the phenotype 
as a dichotomous trait, which results in a loss of information. 
In conclusion, we identified genetic variants located in the APOE region associated with 
BMB, which were more strongly associated with lobar than mixed BMB. Our data also 
demonstrated genetic overlap between mixed BMB, and other features of cerebral small 
vessel disease, emphasizing that they represent part of the cerebral small vessel disease 
spectrum. 
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Tables and figures 
Table legends 
Table 1. Population characteristics of contributing studies. 
Table 2. Independent genetic variants significantly (p<5x10-8) or suggestively (p<1x10-6) 
associated with any or location-specific brain microbleeds. 
Table 3. The effects of APOE ε4 allele count on the number of brain microbleeds overall and 
by location. 
Table 4. Two-sample Mendelian randomization of cardiovascular traits and brain microbleeds 
overall and by location. 
Table 5. Association of subcortical small vessel disease associated genetic variants with brain 
microbleeds overall and by location. 
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Figure legends 
Figure 1. Common genetic variants associated with brain microbleeds. Manhattan plots 
showing genome-wide associations by chromosomal position for (A) any, (B) lobar and (C) 
mixed microbleeds. 
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Figure 2. Regional association of genome-wide significant locus for any brain 
microbleeds. Regional plot showing association of genetic variants in the APOE region with 
any brain microbleeds. 
 
Supplementary Table legends 
Supplementary Table 1. (http://doi.org/10.5061/dryad.mcvdncjz4) Genotyping and quality 
control metrics. 
Supplementary Table 2. (http://doi.org/10.5061/dryad.mcvdncjz4) Image data acquisition and 
processing. 
Supplementary Table 3. (http://doi.org/10.5061/dryad.mcvdncjz4) Genomic inflation and 
polygenicity in the different meta-analyses. 
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Supplementary Table 4. (http://doi.org/10.5061/dryad.mcvdncjz4) Functional annotation of 
genome-wide significant and suggestive genetic variants for brain microbleeds (p<1x10-6) and 
variants in linkage disequilibrium (r2>0.8). 
Supplementary Table 5. (http://doi.org/10.5061/dryad.mcvdncjz4) Independent genome-wide 
significant and suggestive associations (p<1x10-6) with brain microbleeds in a sample 
excluding individuals with dementia or stroke. 
Supplementary Table 6. (http://doi.org/10.5061/dryad.mcvdncjz4) The effects of APOE ε4 
allele count on the number of brain microbleeds overall and by location, excluding individuals 
with the APOE ε2ε4 genotype. 
Supplementary Table 7. (http://doi.org/10.5061/dryad.mcvdncjz4) Association of genetic 
variants for Alzheimer’s disease and stroke with brain microbleeds overall and by location. 
Supplementary Figure legends 
Supplementary Figure 1. (http://doi.org/10.5061/dryad.mcvdncjz4) Quantile-quantile plots 
showing the observed versus expected –log P-value for (A) any, (B) lobar and (C) mixed 
microbleeds. 
Supplementary Figure 2. (http://doi.org/10.5061/dryad.mcvdncjz4) Regional plots of the 
suggestive genetic variants (p<1x10-6) for overall or location-specific microbleeds. 
Supplementary Figure 3. Forest plots showing the study-specific associations between the 
independent genome-wide significant (p<5x10-8) and suggestive (p<1x10-6) genetic variants 
and brain microbleeds, overall and by location. 
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Supplementary Figure 4. Quantile-quantile plots and Manhattan plots presenting the results of 
the genome-wide association studies of (A) any, (B) lobar, and (C) mixed microbleeds in a 
study sample without dementia or stroke. 
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Study Study design Ancestry N total 
N any 
BMB 
N lobar 
BMB N mixed BMB 
N (%) 
female 
Age 
(mean±sd) Age range N demented N stroke 
ADNI 
Case-control (AD, 
MCI, healthy 
controls) European 734 149 95 54 330 (45.0) 73.1 ± 7.5 48 - 94 116 45 
AGES Population-based European 2,894 469 272 197 1,679 (58.0) 76.4 ± 5.5 66 - 95 149 223 
ASPS Population-based European 203 34 NA 28 89 (43.8) 60.1 ± 6.3  46 - 79 0 0 
ARIC (AA) Population-based European 422 118 81 31 281 (66.6 ) 75.4 ± 5.1 67 - 89 24 22 
ARIC (EA) Population-based 
African 
American 1,174 267 184 74 680 (57.9 ) 77.0 ± 5.3 67 - 90 70 34 
CROMIS-2 
AF 
Case-only (stroke 
cases) European 1,238 253 94 158 522 (42.2) 75.1 ± 12.6 35 - 100 32 1,238 
EDIS-SCES Population-based Chinese 130 42 27 NA 69 (53.1) 70.5 ± 6.1 60 - 85 5 6 
EDIS-SiMES Population-based Malay 204 75 36 NA 107 (52.5) 70.6 ± 6.6 60 - 85 21 8 
ERF Family-based European 126 27 15 12 66 (52.4) 64.5 ± 4.6 55 - 75 0 0 
FHS Population-based European 3,968 257 176 81 2,115 (53.3) 57.3 ± 13.6 25 - 96 25 51 
LBC1936 Population-based European 626 74 21 53 295 (47.1) 72.7 ± 0.7 71 - 74 5 43 
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Table 1. Population characteristics of contributing studies.  
LLS Family-based European 279 39 24 11 147 (52.7) 65.8 ± 6.9 45 - 84 0 0 
MGH-
GASROS 
Case-only (stroke 
cases) European 380 106 51 55 127 (36.0) 66.7 ± 15.0 18 - 102 0 353 
PROSPER 
RCT/population-
based European 456 104 74 26 197 (43.2) 75.0 ± 3.2 70 - 83 0 74 
RS1 Population-based European 1,119 384 234 150 642 (57.4) 79.2 ± 5.0 68 - 96 30 64 
RS2 Population-based European 1,206 270 167 103 628 (52.1) 69.7 ± 6.2 60 - 97 8 23 
RS3 Population-based European 2,611 318 237 81 1,444 (55.3) 57.3 ± 6.6 45 - 89 0 3 
UK Biobank Population-based European 8,092 570 391 179 4,263 (52.7) 62.1 ± 7.4 44 - 78 3 75 
   25,862 3,556 2,179 1,293      
Abbreviations: AA, African ancestry; AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; AGES, Age Gene/Environment Susceptibility; ASPS, Austrian 
Stroke Prevention Study; ARIC, Atherosclerosis Risk in Communities; BMB, brain microbleeds; CROMIS-2 AF, Clinical Relevance of Microbleeds In Stroke due to Atrial 
Fibrillation; EA, European ancestry; EDIS, Epidemiology of Dementia in Singapore; ERF, Erasmus Rucphen Family; FHS, Framingham Heart Study; LBC1936, Lothian Birth 
Cohort 1936; LLS, Leiden Longevity Study; MCI, mild cognitive impairment; MGH-GASROS, Massachusetts General Hospital Genes Affecting Stroke Risk and Outcomes Study; N, 
number of subjects; PROSPER, PROspective Study of Pravastatin in the Elderly at Risk; RCT, randomized controlled trial; RS, Rotterdam Study; SCES, Singapore Chinese Eye 
Study; sd, standard deviation; SiMES, Singapore Malay Eye Study. 
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Table 2. Independent genetic variants significantly (p<5x10-8) or suggestively (p<1x10-6) associated with any or location-
specific brain microbleeds. 
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SNP Chr Position A1 A2 EAF Nearest gene Outcome Beta SE OR N total N cases P-value 
rs769449 19 45410002 A G 0.13 APOE Any BMB 0.282 0.045 1.33 20,150 2,858 2.5 x 10-10 
       Lobar BMB 0.280 0.055 1.32 18,666 1,748 4.3 x 10-7
       Mixed BMB 0.243 0.070 1.27 18,319 1,049 5.4 x 10-4 
rs6950978 7 87200467 A T 0.70 ABCB1 Any BMB -0.154 0.030 0.86 25,528 3,439 2.7 x 10-7 
       Lobar BMB -0.153 0.037 0.86 24,101 2,101 4.1 x 10-5  
       Mixed BMB -0.179 0.046 0.84 23,033 1,239 1.0 x 10-4 
rs7533718 1 22281393 A G 0.83 HSPG2 Any BMB -0.140 0.042 0.87 25,402 3,412 7.5 x 10-4 
       Lobar BMB -0.263 0.051 0.77 22,935 2,005 2.9 x 10-7 
       Mixed BMB 0.003 0.070 1.00 22,446 1,161 9.7 x 10-1 
rs11025317 11 3103445 A G 0.12 OSBPL5 Any BMB 0.172 0.049 1.19 20,330 2,918 4.3 x 10-4 
       Lobar BMB 0.305 0.060 1.36 18,666 1,748 3.0 x 10-7 
       Mixed BMB -0.027 0.082 0.97 17,714 996 7.4 x 10-1 
rs62522567 8 103799094 A G 0.92 GASAL1 Any BMB -0.231 0.051 0.79 24,118 3,115 6.9 x 10-6 
       Lobar BMB -0.319 0.063 0.73 22,550 1,924 4.0 x 10-7 
       Mixed BMB -0.195 0.089 0.82 17,075 942 2.8 x 10-2 
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rs1058285 19 43680051 T C 0.61 PSG5 Any BMB 0.082 0.030 1.08 24,794 3,290 6.0 x 10-3 
       Lobar BMB 0.188 0.038 1.21 23,535 2,021 5.3 x 10-7 
       Mixed BMB -0.051 0.045 0.95 22,729 1,216 2.6 x10-1 
rs654240 11 69448373 T C 0.41 CCND1 Any BMB 0.154 0.031 1.17 25,402 3,412 7.4 x 10-7  
       Lobar BMB 0.116 0.039 1.12 23,528 2,080 2.8 x 10-3 
       Mixed BMB 0.202 0.048 1.22 23,368 1,270 3.0 x 10-5 
Table presenting the associations with brain microbleeds with a p<1x10-6. If available, the associations of the same genetic variants in the 
other analyses are also shown. Abbreviations: A1, effect allele; A2, other allele; BMB, brain microbleeds; Chr, chromosome; EAF, effect allele 
frequency; N, number of subjects; OR, odds ratio; P, p-value; SE, standard error; SNP, single nucleotide polymorphism. 
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Table 3. The effects of APOE ε2 and 4 allele count on the number of brain 
microbleeds overall and by location. 
Outcome Beta SE OR (95% CI) P-value 
APOE ε2 allele count 
All BMB 0.026 0.089 1.03 (0.86-1.22) 0.769 
Lobar BMB 0.130 0.121 1.14 (0.90-1.44) 0.283 
Mixed BMB -0.243 0.178 0.78 (0.55-1.11) 0.171 
APOE ε4 allele count 
All BMB 0.242 0.055 1.27 (1.14-1.42) 1.3 x 10-5 
Lobar BMB 0.285 0.069 1.33 (1.16-1.52) 3.5 x 10-5 
Mixed BMB 0.069 0.117 1.07 (0.85-1.35) 0.553 
Abbreviations: BMB, brain microbleeds; CI, confidence interval; OR, odds ratio; SE, 
standard error. 
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Table 4. Two-sample Mendelian randomization of cardiovascular traits and brain 
microbleeds overall and by location. 
Analysis Estimate (95% CI) P-value 
Any brain microbleeds 
Type 2 diabetes -0.072 (-0.176-0.031) 0.170 
Systolic blood pressure 0.026 (0.005-0.046) 0.013* 
Diastolic blood pressure 0.046 (0.010-0.082) 0.011* 
Pulse pressure 0.021 (-0.008-0.049) 0.156 
Body mass index -0.037 (-0.131-0.057) 0.445 
Low density lipoprotein 0.057 (-0.085-0.198) 0.431 
High density lipoprotein -0.001 (-0.159-0.157) 0.990 
Triglycerides 0.290 (0.090-0.489) 0.004** 
Lobar brain microbleeds 
Type 2 diabetes -0.053 (-0.180-0.074) 0.414 
Systolic blood pressure 0.027 (0.003-0.051) 0.029* 
Diastolic blood pressure 0.046 (0.003-0.088) 0.035* 
Pulse pressure 0.023 (-0.010-0.057) 0.174 
Body mass index -0.023 (-0.141-0.094) 0.697 
Low density lipoprotein 0.145 (-0.015-0.306) 0.076 
High density lipoprotein -0.024 (-0.206-0.159) 0.799 
Triglycerides 0.250 (0.015-0.486) 0.037* 
Mixed brain microbleeds 
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Type 2 diabetes -0.074 (-0.222-0.073) 0.323 
Systolic blood pressure 0.024 (-0.005-0.054) 0.108 
Diastolic blood pressure 0.034 (-0.019-0.086) 0.209 
Pulse pressure 0.025 (-0.017-0.066) 0.243 
Body mass index -0.047 (-0.191-0.097) 0.524 
Low density lipoprotein -0.078 (-0.315-0.159) 0.519 
High density lipoprotein -0.050 (-0.263-0.162) 0.642 
Triglycerides 0.374 (0.094-0.654) 0.009* 
Nominally significant associations are denoted by an asterisk (*; p<0.05), associations 
significant after adjustment for the number of risk factors by two asterisks (**; p<(0.05/8)). 
Abbreviations: CI, confidence interval. 
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Table 5. Association of cerebral small vessel disease associated genetic variants 
with brain microbleeds overall and by location. 
   All BMB Lobar BMB Mixed BMB 
Trait Locus SNP OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
1q22 rs2984613 1.12 (1.05-1.18) 0.0002** 1.09 (1.01-1.17) 0.022** 1.14 (1.05-1.25) 0.003** ICH deep 
13q34 rs4771674 1.03 (0.97-1.09) 0.350 0.99 (0.93-1.07) 0.879 1.06 (0.97-1.15) 0.218 
16q24 rs12445022 1.07 (1.00-1.13) 0.034* 1.04 (0.97-1.12) 0.277 1.10 (1.00-1.20) 0.039* 
10q26 rs79043147 1.02 (0.91-1.14) 0.785 1.04 (0.90-1.21) 0.601 1.05 (0.87-1.27) 0.582 
Lacunar 
stroke 
13q34 rs9515201 1.04 (0.98-1.10) 0.206 0.98 (0.91-1.06) 0.684 1.12 (1.02-1.22) 0.014** 
2p21 rs11679640 0.95 (0.88-1.01) 0.111 0.96 (0.88-1.04) 0.300 0.98 (0.88-1.10) 0.768 
10q24 rs12357919 1.01 (0.94-1.08) 0.881 1.00 (0.91-1.10) 0.970 0.97 (0.86-1.09) 0.598 
6q25 rs275350 1.01 (0.95-1.06) 0.775 0.98 (0.91-1.05) 0.519 1.08 (0.99-1.17) 0.084 
1q22 rs2984613 1.12 (1.05-1.18) 0.0002** 1.09 (1.01-1.17) 0.022* 1.14 (1.05-1.25) 0.003** 
17q25 rs7214628 1.00 (0.94-1.08) 0.902 1.04 (0.95-1.13) 0.404 1.02 (0.91-1.13) 0.779 
10q24 rs72848980 1.00 (0.93-1.08) 0.947 1.00 (0.91-1.10) 0.970 0.98 (0.87-1.10) 0.687 
2q33 rs72934505 1.05 (0.96-1.15) 0.264 1.01 (0.91-1.12) 0.886 1.11 (0.97-1.27) 0.141 
2p16 rs78857879 1.06 (0.97-1.17) 0.206 1.02 (0.91-1.16) 0.695 1.08 (0.93-1.25) 0.300 
10q24 rs7894407 1.04 (0.98-1.10) 0.212 1.01 (0.94-1.09) 0.772 1.02 (0.94-1.12) 0.605 
10q24 rs7909791 0.99 (0.94-1.05) 0.784 0.99 (0.92-1.06) 0.737 0.96 (0.88-1.05) 0.420 
14q32 rs941898 0.95 (0.89-1.01) 0.117 0.91 (0.84-0.99) 0.026* 1.01 (0.92-1.12) 0.817 
13q34 rs9515201 1.04 (0.98-1.10) 0.206 0.98 (0.91-1.06) 0.684 1.12 (1.02-1.22) 0.014* 
17q21 rs962888 1.02 (0.96-1.08) 0.570 1.01 (0.93-1.09) 0.868 1.02 (0.93-1.12) 0.641 
WMH 
 Overall 1.29 (0.97-1.72) 0.074 1.02 (0.71-1.45) 0.927 1.78 (1.15-2.77) 0.010* 
Odds ratios aligned to risk allele from original studies. Significance levels are denoted by asterisks: *, nominally significant (p<0.05); 
**, significant after Bonferroni correction (p<0.05/number of genetic variants). † In the overall score for WMH rs12357919 was left 
out since this genetic variant was in linkage disequilibrium (r2>0.2) with rs72848980. Abbreviations: BMB, brain microbleeds; CI, 
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confidence interval; ICH, intracerebral haemorrhage; OR, odds ratio; SNP, single nucleotide polymorphism; WMH, white matter 
hyperintensities. 
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